for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Interpace Diagnostics Group Inc

IDXG.OQ

Latest Trade

0.79USD

Change

0.03(+3.63%)

Volume

25,053

Today's Range

0.75

 - 

0.79

52 Week Range

0.67

 - 

1.78

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.76
Open
0.76
Volume
25,053
3M AVG Volume
4.06
Today's High
0.79
Today's Low
0.75
52 Week High
1.78
52 Week Low
0.67
Shares Out (MIL)
38.20
Market Cap (MIL)
29.06
Forward P/E
-1.87
Dividend (Yield %)
--

Latest Developments

More

Interpace Diagnostics Reports Qtrly Loss Per Share $0.14

Interpace Announces New Agreement With SelectHealth

Interpace Diagnostics Acquires Cancer Genetics' Biopharma Services Business

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Interpace Diagnostics Group Inc

Interpace Diagnostics Group, Inc., formerly PDI, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, the Company provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.

Industry

Healthcare Facilities

Contact Info

Morris Corporate Center 1

, Building C, 300 Interpace Parkway

+1.412.2246100

http://www.interpacediagnostics.com/

Executive Leadership

Stephen J. Sullivan

Chairman of the Board

Jack E. Stover

President, Chief Executive Officer, Director

James Early

Chief Financial Officer, Treasurer, Secretary

Gregory Richard

Senior Vice President, Chief Commercial Officer

Eric B Lev

Non-Executive Director

Key Stats

1.80 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2017

-0.650

2018

-0.430

2019(E)

-0.407
Price To Earnings (TTM)
--
Price To Sales (TTM)
1.22
Price To Book (MRQ)
0.94
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-39.91
Return on Equity (TTM)
-32.72

Latest News

BRIEF-Interpace Diagnostics Enters Agreement With Integrated Health Systems

* INTERPACE DIAGNOSTICS ENTERS AGREEMENT WITH ONE OF THE LARGEST, INTEGRATED HEALTH SYSTEMS IN THE US

BRIEF-Interpace Diagnostics Announces Agreement With Acupath Laboratories

* INTERPACE DIAGNOSTICS ANNOUNCES AGREEMENT WITH ACUPATH LABORATORIES

BRIEF-Interpace Diagnostics Announces Additional Coverage of Thyroid Tests

* INTERPACE DIAGNOSTICS - 4 ADDITIONAL BLUE CROSS BLUE SHIELD PLANS AGREED TO COVER BOTH OF INTERPACE'S PROPRIETARY THYROID TESTS, THYGENX AND THYRAMIR Source text for Eikon: Further company coverage:

BRIEF-Interpace Diagnostics Group Entered A Laboratory Services Agreement With Arup Laboratories

* INTERPACE DIAGNOSTICS GROUP INC - HAS ENTERED INTO A LABORATORY SERVICES AGREEMENT WITH ARUP LABORATORIES, INC OF SALT LAKE CITY, UTAH

BRIEF-Interpace Diagnostics says Q3 sales up 27 pct

* Interpace diagnostics group reports third quarter 2017 financial results, business progress and recent accomplishments

BRIEF-Interpace Diagnostics announces increased reimbursement for ThyGenX

* Interpace Diagnostics Group - reimbursement for ThyGenx molecular test for indeterminate thyroid nodules will increase by 40% starting Jan 1, 2018 Source text for Eikon: Further company coverage:

BRIEF-Interpace Diagnostics ‍launches new lung cancer test MVPdX​

* Interpace Diagnostics Group Inc - Launch of a new lung cancer test MVPdX Source text for Eikon: Further company coverage:

BRIEF-Interpace Diagnostics Group Inc - ‍ assigned a new, discreet CPT code to facilitate reimbursement of Thyramir​

* Interpace Diagnostics Group Inc - assigned a new, discreet CPT code to facilitate reimbursement of Thyramir

BRIEF-Interpace Diagnostics announces renewal and extension of LabCorp national agreement

* Interpace Diagnostics announces renewal and extension of LabCorp national agreement

BRIEF-Interpace Diagnostics reports Q2 ‍loss per share from cont ops of $0.65

* Interpace Diagnostics Group reports second quarter 2017 financial results, business progress and recent accomplishments

BRIEF-Interpace Diagnostics launches product extension at world conference on thyroid cancer

* Interpace Diagnostics launches product extension at world conference on thyroid cancer Source text for Eikon: Further company coverage:

BRIEF-Interpace Diagnostics says Cigna agreed to cover co's ThyGenx test for Cigna members

* Interpace diagnostics group inc - cigna agreed to cover interpace's thygenx test for cigna members nationwide, with coverage effective immediately Source text for Eikon: Further company coverage:

BRIEF-Interpace Diagnostics announces national contract with Aetna

* Interpace Diagnostics announces national contract with Aetna

BRIEF-Interpace Diagnostics announces coverage of thyroid test by Premera Blue Cross

* Interpace Diagnostics Group - Premera Blue cross agreed to cover co's Thyramir test for members located primarily in Washington, Oregon, and Alaska Source text for Eikon: Further company coverage:

BRIEF-Armistice Capital Llc reports 4.99 pct passive stake in Interpace Diagnostics Group

* Armistice Capital LLC reports 4.99 Pct Passive Stake in Interpace Diagnostics Group Inc as of June 16 Source text: (http://bit.ly/2szWxxP) Further company coverage:

BRIEF-Interpace Diagnostics announces pricing

* Interpace Diagnostics announces pricing of $13.7 million underwritten public offering of common stock and common warrants

BRIEF-Interpace Diagnostics files for offering of up to $13.8 mln

* Interpace Diagnostics Group - offering for shares of co's common stock and pre-funded warrants to purchase shares of its common stock Source text:(http://bit.ly/2rsQhba) Further company coverage:

BRIEF-Interpace Diagnostics qtrly EPS from continuing operations $0.42

* Interpace diagnostics group reports first quarter 2017 financial results, business progress and recent accomplishments

BRIEF-Interpace Diagnostics eliminates long term secured debt

* Interpace Diagnostics - on April 18, 2017 a institutional investor exchanged $3.5 million secured note for a $3.5 million secured convertible note issued by co

BRIEF-Interpace Diagnostics announces receipt of letter from Nasdaq confirming compliance with minimum stockholders' equity requirement

* Interpace Diagnostics announces receipt of letter from Nasdaq confirming compliance with minimum stockholders' equity requirement Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up